This work was carried out by a great team @DianaPelizzari @ddoultsinos @ChloeSauzay @avril_tony @aristotle71 @Eric_Chevet and the twitterless #XavierGuillory #LeifAEriksson #RaphaelPineau #antonio_carlesso #thodoris_koutsandreas #elena_gkotsi

thanks to our funders @Inserm_EN @UnivRennes1 @chimie_ISCR @Eugene_Marquis @INCa_veillePro @AgenceRecherche @FRM_officiel @TRAIN_ERS @MSCActions @FondationARC #INCR #swedish_research_council

and prevented tumor relapse when administered together with temozolomide.

and as such the new BBB permeable IRE1 inhibitor was tested on glioblastoma lines and mouse models. In vivo, this showed that the compound was indeed effective on glioblastoma tumors when administered i.p.

As previoulsy shown IRE1 inhibition may improve the standard of care in glioblastoma

and identifies a novel family of IRE1 inhibitors among which one is predicted to pass through the BBB

In this manuscript, the team uses a structure-based discovery pipeline, similar to that used in FEBS Press

Latest preprint from the lab "A novel blood brain barrier-permeable IRE1 kinase inhibitor sensitizes glioblastoma to chemotherapy in mice" great collaboration thanks to @DianaPelizzari #XavierGuillory #LeifAEriksson

Happy to say that Inserm U1242 "Oncogenesis, Stress, Signaling" has been renewed for the next 5 (6) years. Three teams & about 90 engaged personnel collectively focusing on cancer research 👏👏👏 @inserm @UnivRennes1 @Eugene_Marquis

👏👏👏👏👏👏 @C_LOUIS1, @Delphine_Lclrc and @CoulouarnC for their review on circRNA in liver cancer